MADRID, May 9, 2024 /PRNewswire/ -- mAbxience, a
Fresenius Kabi majority-owned group with partial ownership from
Insud Pharma, is pleased to announce the appointment of
Jurgen Van Broeck as Chief Executive
Officer. Jurgen, who has served as Global Commercial Director since
June 2023, brings a great deal of
experience and a proven track record in the pharmaceutical and
biosimilars industries.
Prior to his new role, Jurgen has been at the forefront of
mAbxience's strategic initiatives, overseeing all commercial,
business development and market access activities. He has been
instrumental in steering the company's strategic partnering and
establishing the growth trajectory of our CDMO services. Under his
leadership, mAbxience has successfully enhanced its global presence
and continued to excel in delivering accessible, high-quality
medicines worldwide.
Jurgen joined mAbxience with nearly two decades of extensive
experience in the healthcare sector, including significant roles at
multinational corporations such as Merck and Mundipharma. His
expertise has been particularly impactful in the launch of the
first immunology biosimilar across multiple regions, in driving
substantial in- and out-licensing deals and steering commercial
operations in multiple regions.
Jurgen commented on his new role, saying, "I am honored to
lead mAbxience in this exciting growth phase of the company as we
continue to strive for excellence in everything we do. Our mission
to provide quality, affordable biological medicines and deliver
worldclass CDMO services, remain at the core of our strategy. I
look forward to working closely with our talented team to advance
our pipeline, expand our global footprint and become a world known
CDMO for biologics."
mAbxience remains committed to its mission of enhancing the
quality of life through universal access to high-quality
biopharmaceuticals. With a robust product pipeline and strategic
partnerships across over 100 markets, mAbxience is set to maintain
its trajectory as a leading force in the global biopharmaceutical
landscape under Jurgen's leadership.
About mAbxience
mAbxience is a Spanish-based company
specializing in the development, production, and commercialization
of biopharmaceuticals. In August
2022, Fresenius Kabi and Insud Pharma entered into an
agreement whereby Fresenius Kabi acquired a majority stake of
mAbxience, making it a global, vertically integrated biotechnology
company. Fresenius Kabi is an operating company of the global
health care organization Fresenius.
For more insights into mAbxience, our biosimilars and CDMO
business, please visit our website (www.mabxience.com) or connect
with us on LinkedIn.
Photo:
https://mma.prnewswire.com/media/2408752/Jurgen_Van_Broeck.jpg
View original
content:https://www.prnewswire.com/news-releases/mabxience-appoints-jurgen-van-broeck-as-new-ceo-302141331.html
SOURCE mAbxience